title: [Chronic hepatitis C and HIV. Current therapeutic options].
abstract: A co-infection with HCV and HIV promotes the development of liver cirrhosis. The avoidance of this hepatic death-trap is therefore the primary aim of treatment for hepatitis C. Up until the end of the year 2000, the standard therapy for hepatitis C in HIV-negative patients was the combination of interferon alpha and ribaverin. The pegylated interferons that became available last year appear to offer advantages. For patients co-infected with HIV, however, no studies have so far been carried out. Combination "partners" of interferon capable of replacing or supplementing ribaveron are presently in the clinical development stage.
authors.forename: S
authors.initials: S
authors.lastname: Mauss
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D011994:Recombinant Proteins
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a